Sickle cell disease (SCD) is associated with significant morbidity, and allogeneic hematopoietic stem cell transplantation (HSCT) remains the primary curative treatment. Recently, the Brazilian Ministry of Health released a regulation that required the publically funded healthcare system to pay for HSCT for SCD patients with defined indications. We used an existing 2794-member SCD cohort established during 2013 to 2015 to characterize candidates for HSCT and estimate the number of possible donors. Of 2064 patients with SC anemia (SCA), 152 of 974 children (16%) and 279 of 1090 adults (26%) had at least 1 HSCT indication. The most common indication for transplant was stroke (n = 239) followed by avascular necrosis (n = 96), priapism (n = 82), cerebrovascular disease (n = 55), >2 vaso-occlusive episodes (n = 38), alloantibodies and chronic transfusion therapy (n = 18), and >2 acute chest syndrome episodes (n = 11). Increasing age, number of transfusions, abnormal transcranial Doppler, retinopathy, dactylitis, and use of hydroxyurea were more frequent in the 152 children with an indication for HSCT compared with 822 without (P < .001). Of 152 children and 279 adults meeting the eligibility definition, 77 (50%) and 204 (73%), respectively, had at least 1 non-SCD full sibling who could potentially serve as a donor. In conclusion, in a large cohort of SCA patients, 16% of children and 26% of adults had at least 1 indication for HSCT; these indications were associated with the severity of the disease. This study provides clinical data necessary for estimating the costs and infrastructure that would be required to implement HSCT in a public healthcare system.
Identification and characterization of hematopoietic stem cell transplant candidates in a sickle cell disease cohort
Flor-Park, M., Kelly, S., Preiss, L., Custer, B., Carneiro-Proietti, A. B. F., Araujo, A. S., Loureiro, P., Maximo, C., Rodrigues, D. O. W., Mota, R. A., Sabino, E. C., Rocha, V., & NHLBI Recipient Epidemiology Donor (2019). Identification and characterization of hematopoietic stem cell transplant candidates in a sickle cell disease cohort. Biology of Blood and Marrow Transplantation, 25(10), 2103-2109. https://doi.org/10.1016/j.bbmt.2019.06.013